The resolution of the proxy contest removes a key overhang and may stabilize the stock near term. Traders should watch for any disclosed board changes or additional details on the settlement, and then shift focus to upcoming clinical catalysts for the oral vaccine pipeline.
Price Chart
Executive Summary
Vaxart has reached an agreement with a group of shareholders to resolve its ongoing proxy contest, as announced via DEFA14A. The settlement removes near-term board-election uncertainty and allows management to focus on clinical and operational milestones for its oral vaccine platform.
Key Facts
- Vaxart announced an agreement with a group of shareholders to resolve its proxy contest.
- The company states it remains committed to corporate governance and shareholder engagement.
- Management reiterated focus on upcoming clinical, regulatory and operational milestones.
- The settlement follows a preliminary proxy filing (PREC14A) that indicated a contested director election from stockholder Daniel P. Houle.
Financial Impact
Not specified
Risk Factors
- Terms of the shareholder agreement are not disclosed; any concessions could affect governance dynamics.
- The company remains a clinical-stage biotech with no approved products, and pipeline execution risk persists.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-075088 |
| Document: 0001213900-26-075088-index-headers.html | 0001213900-26-075088 |
| Document: 0001213900-26-075088-index.html | 0001213900-26-075088 |
| Document: 0001213900-26-075088.txt | 0001213900-26-075088 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $0.4800 $0.5000 | ▲ +4.17% | ▲ +0.79% | $0.4400 (−8.33%) |
Jul 7, 2026 12w ago | 8-K | $0.5500 $0.6000 | ▲ +9.09% | ▲ +5.93% | $0.4400 (−20.00%) |
Jul 6, 2026 12w ago | DEFA14A | $0.6200 $0.5900 | ▼ −4.84% | ▼ −5.69% | $0.4400 (−29.03%) |
Jul 2, 2026 13w ago | DEFA14A | $0.6400 $0.5490 | ▼ −14.22% | ▼ −14.52% | $0.4400 (−31.25%) |
Jul 2, 2026 13w ago | 8-K | $0.6400 $0.5200 | ▼ −18.75% | ▼ −18.34% | $0.4400 (−31.25%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 26, 2026 13w ago | 8-K | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 16, 2026 15w ago | DEFA14A | $0.5600 $0.5300 | ▼ −5.36% | ▼ −6.21% | $0.4400 (−21.43%) |
Jun 8, 2026 16w ago | DEFA14A | $0.5800 $0.5502 | ▼ −5.14% | ▼ −6.53% | $0.4400 (−24.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access